Titan Pharmaceuticals Schedules Conference Call To Review Third Quarter 2018 Financial Results November 8, 2018
Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer October 2, 2018
Titan Awarded NIDA Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse September 10, 2018
Titan And The Nevada Center For Behavioral Health Collaborate To Evaluate Probuphine® Treament Of OUD Patients Within The State Of Nevada Criminal Justice System September 4, 2018
Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program July 2, 2018
Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence May 30, 2018
